Our History

CinnaGen Co. was founded in 1994 with the goal of manufacturing hi-tech products in biotechnology and related fields. Since its start of operation with 4 scientists, CinnaGen has grown to become the biggest bio-pharmaceutical manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products to cover regional markets. Enzymes, molecular biology reagents and PCR kits were the first products and then CinnaGen used its proprietary set of technologies to endow monoclonal antibodies for blood group typing. The next important step for CinnaGen was to enter therapeutic recombinant proteins and monoclonal antibodies area.

Today the company prides itself in its innovative skills meeting today challenges. We focus our efforts on developing the biosimilar candidates in the areas of Immunological diseases, MS, Infertility, Diabetes, Kidney diseases, Osteoporosis, Hormone disorders and Oncology as well as providing contract research development services. The company is spending over 20 percent of its total turnover on R&D activities.

CinnaGen is strategically positioned to become and remain a leading biotechnology company in the region. Our aim is to use our expertise to identify and acquire selected products through strategic partnerships to promote sustainable development in human health.
1994 1995 1997 1999 2000 2002 2004 2005 2006 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
  • 1994

    Estabilishment of the CinnaGen

    CinnaGen Co. was established in 1994 by a group of young Iranian scientists.


  • 1995

    Production and Marketing of Taq DNA polymerase

    CinnaGen Co. is the 1st Iranian Taq DNA polymerase manufacturer in the MENA region.

  • 1997

    Production and Marketing of Molecular Diagnostic kits(PCR-based technology)

  • 1999

    Production of ABO grouping kit-entering the area of diagnostic monoclonal antibodies production

    CinnaGen is the 1st Monoclonal Antibody producer in MENA region.


  • 2000

    Pharmaceutical Synthetic Peptides Production

    Production of GnRH-entering the area of pharmaceutical synthetic peptides production


  • 2000

    ISO Granted

    ISO 9001:1994 Granted

  • 2002

    New Biotechnology Services

    Primer synthesis service

    DNA sequencing service

    Production of Restriction enzymes

  • 2004

    Construct SD1

    Inauguration of manufacturing-plant in Simindasht-Karaj (record breaking construction in 10 months)

    Production of Busereline-Acetate

  • 2005

    Pharmaceutical Era

    Starting Clinical Trial of CinnoVex (rec Hu-IFN beta 1a)

    Production of active pharmaceutical ingredient of rec Hu-erythropoietin beta

    ISO 9001:2000 Granted

  • 2006

    First Recombinant Drug, Now in Market

    Launching CinnoVex in the local market as the second producer in the world after Biogen-Idec

    GMP Certificate granted by MOH of I.R.Iran

  • 2006

    CinnoVex Launch

    CinnaGen get release license of CinnoVex (interferon Beta- 1a) from Iranian FDO.

  • 2008

    Powering up

    Starting Clinical Trial of Betapoietin and ReciGen(rec Hu-IFN beta 1a-44 microgram)

    Cooperation with Dr. Reddy-India for Technology transfer of Rituximab

    rec Hu-FSH in the pipeline rec Hu-PTH in the pipeline

    ISO 13485:2003 and 9001:2008 Granted

  • 2008

    High Dose Achieved

    Launching ReciGen(rec Hu-IFN beta 1a-44microgerams)

    Production of Reditux™(Rituximab) therapeutic monoclonal antibody

    Rec Hu-PEG-GCSF in the pipeline

  • 2009

    ReciGen Launch

    CinnaGen got release license of ReiGen (interferon Beta- 1a) from Iranian FDO.

  • 2010

    Beyond the Boundaries

    Registration of CinnoVex™ in Russia, Syria and Armenia

    Launching Betapoietin (rec Hu-EPO beta)

    Starting Clinical Trial of CinnoPar (rec Hu-PTH)

  • 2011

    New Building

    Commencing the construction of a new production facility SD2.

    Launching Reditux™ (Rituximab)as the first Monoclonal antibody produced in Iran

    Launching CinnaFact (Buserelin Acetate)

  • 2011

    CinnaFact Launch

    CinnaGen got release license of CinnaFact (Buserelin) from Iranian FDO.

  • 2012

    GMP based on EMA Regulations

    Commencing the construction of a new warehouse facility SD3 (Simin dasht-3)

    Qualification and running of new state of the art GMP facility (SD-2) based on EMA Regulations.

    Registration of ReciGen® in Syria

    Registration of CinnoVex™ in Azerbaijan

  • 2013

    Expanding our basket

    Launching Cinnal f® (Follitropin alfa)as the first follitropin biosimilar produced in Iran

    Launching CinnoPar® (Teriparatide) as the first parathyroid hormone (1-34) biosimilar produced in Iran

    Launching CinnaPoietin® (rec Hu-EPO beta)

    Launching PegaGen® (Peg-filgrastim) as the first Pegylated filgrastim biosimilar produced in Iran

    Launching Recigen in Syria

  • 2013

    CinnoPar Launch

    CinnaGen got release license of CinnoPar (Parathyroid Hormone) from Iranian FDO.

  • 2013

    Cinnal-f Launch

    CinnaGen got release license of Cinnal-f (Follitropin alfa) from Iranian FDO.

  • 2014

    PegaGen Launch

    CinnaGen got release license of PegaGen (Pegylated Filgrastim) from Iranian FDO.

  • 2014

    CinnaPoietin Launch

    CinnaGen got release license of CinnaPoietin (Erythropoietin) from Iranian FDO.

  • 2015

    CinnoMer Launch

    CinnaGen got release license of CinnoMer (Glatiramer) from Iranian FDO.

  • 2015

    CinnoTec Launch

    CinnaGen got release license of CinnoTec (Dimethyl Fumarate) from Iranian FDO.

  • 2016

    CinnoRA Launch

    CinnaGen got release license of CinnoRA(Adalimumab)from Iranian FDO

  • 2016

    Facility and Capacity Expansion

    opening of SD-4 with capacity expansion to 13000 liters Bioreactor, First GMP Approved cartridge filling and pen assembly line in IRAN.


  • 2016

    New Era in quality

    Outlook of EU registration in 2020: starting phase I clinical trial in Europe for CinnoVex

  • 2016

    Estabilishment of the CinnaGen İlaç

    CinnaGen Pharmaceutical Group established a new company in Turkey in name of CinnaGen ilaç

  • 2017

    CinnaTropin Launch

    CinnaGen got release license of CinnaTropin(Somatropin)  From Iranian FDA.

  • 2017

    New Treatment, New Hope

    Starting clinical trials for new biosimilars; Pertuzumab, Cetuximab, Eculizumab, pegylated Interferon beta, Liraglutide


  • 2017

    KidiPeg Launch

    CinnaGen got release license of KidiPeg (Pegylated Filgrastim) From Iranian FDA.

  • 2017

    New Building

    Staring construction of new facility in Çerkezköy  in the Marmara Region of Turkey.

  • 2017

    New Building

    Staring construction of new facility, SD-5

  • 2018

    Eu GMP Certification

    CinnaGen obtain GMP certification from the European Union.


  • 2019

    CinnaGen ilac has been established in 2019

    This company is the first full cycle manufacturing site to produce biosimilars in Turkey.

  • 2019

    Facility and Capacity Expansion

    Opening of SD-5 Facility and Capacity Expansion with EU GMP Approved